PriceTargets.com logo

Accolade - ACCD Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $8.96
  • Forecasted Upside: 161.94%
  • Number of Analysts: 14
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 11 Buy Ratings
  • 0 Strong Buy Ratings
$3.42 As of 12/24/2024 12:32 PM ET
▼ -0.03 (-0.87%)

This chart shows the closing price for ACCD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Accolade Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ACCD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ACCD

Analyst Price Target is $8.96
▲ +161.94% Upside Potential
This price target is based on 14 analysts offering 12 month price targets for Accolade in the last 3 months. The average price target is $8.96, with a high forecast of $16.00 and a low forecast of $5.00. The average price target represents a 161.94% upside from the last price of $3.42.

This chart shows the closing price for ACCD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 14 investment analysts is to moderate buy stock in Accolade. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 11 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
7/3/2023
  • 0 strong buy ratings
  • 10 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
10/1/2023
  • 0 strong buy ratings
  • 10 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
12/30/2023
  • 0 strong buy ratings
  • 12 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
3/29/2024
  • 0 strong buy ratings
  • 12 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
6/27/2024
  • 0 strong buy ratings
  • 12 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
9/25/2024
  • 0 strong buy ratings
  • 12 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
11/24/2024
  • 0 strong buy ratings
  • 11 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
12/24/2024

Latest Recommendations

  • 0 strong buy ratings
  • 11 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/17/2024Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$6.00 ➝ $5.00
10/11/2024Wells Fargo & CompanyLower TargetEqual Weight ➝ Equal Weight$7.00 ➝ $6.00
10/9/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$13.00 ➝ $7.00
10/9/2024Truist FinancialLower TargetBuy ➝ Buy$9.00 ➝ $7.50
10/9/2024StephensLower TargetOverweight ➝ Overweight$10.00 ➝ $8.00
10/9/2024BarclaysLower TargetEqual Weight ➝ Equal Weight$5.50 ➝ $5.00
10/7/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
6/28/2024Stifel NicolausLower TargetBuy ➝ Buy$13.00 ➝ $8.00
6/28/2024GuggenheimLower TargetBuy ➝ Buy$13.00 ➝ $6.00
6/28/2024BarclaysLower TargetEqual Weight ➝ Equal Weight$11.00 ➝ $5.50
6/28/2024Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$12.00 ➝ $6.00
6/28/2024Truist FinancialLower TargetBuy ➝ Buy$14.00 ➝ $9.00
6/28/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$16.00 ➝ $13.00
6/24/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$13.00 ➝ $13.00
5/8/2024GuggenheimLower TargetBuy ➝ Buy$17.00 ➝ $13.00
4/30/2024Wells Fargo & CompanyLower TargetEqual Weight ➝ Equal Weight$12.00 ➝ $10.00
4/26/2024Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$13.00 ➝ $12.00
4/26/2024Truist FinancialLower TargetBuy ➝ Buy$16.00 ➝ $14.00
4/26/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$18.00 ➝ $16.00
4/26/2024Needham & Company LLCLower TargetBuy ➝ Buy$17.00 ➝ $13.00
4/26/2024BarclaysLower TargetEqual Weight ➝ Equal Weight$13.00 ➝ $11.00
4/22/2024Stifel NicolausLower TargetBuy ➝ Buy$15.00 ➝ $13.00
2/26/2024Leerink PartnrsReiterated RatingOutperform
2/26/2024Leerink PartnersInitiated CoverageOutperform$16.00
1/19/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$17.00
1/9/2024Truist FinancialBoost TargetBuy ➝ Buy$15.00 ➝ $16.00
1/9/2024William BlairReiterated RatingOutperform
1/9/2024Wells Fargo & CompanyBoost TargetEqual Weight ➝ Equal Weight$10.00 ➝ $12.00
1/9/2024Piper SandlerBoost TargetOverweight ➝ Overweight$12.00 ➝ $15.00
1/9/2024Raymond JamesBoost TargetOutperform ➝ Outperform$12.00 ➝ $16.00
1/4/2024Stifel NicolausLower TargetBuy ➝ Buy$17.00 ➝ $15.00
1/3/2024BarclaysInitiated CoverageEqual Weight$13.00
12/6/2023DA DavidsonReiterated RatingBuy
11/22/2023Piper SandlerLower TargetOverweight ➝ Overweight$15.00 ➝ $12.00
10/11/2023Wells Fargo & CompanyLower Target$14.00 ➝ $10.00
10/5/2023Canaccord Genuity GroupLower TargetBuy ➝ Buy$18.00 ➝ $17.00
10/5/2023Truist FinancialLower Target$17.00 ➝ $15.00
10/5/2023StephensReiterated RatingOverweight ➝ Overweight$18.00
10/5/2023Raymond JamesLower TargetOutperform ➝ Outperform$15.00 ➝ $12.00
10/5/2023Bank of AmericaLower Target$19.00 ➝ $16.00
10/2/2023Truist FinancialReiterated RatingBuy ➝ Buy$17.00
10/2/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$17.00
8/14/2023StephensReiterated RatingOverweight ➝ Overweight$18.00
6/30/2023Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$14.00
6/30/2023VNET GroupReiterated RatingReiterates
6/30/2023GuggenheimBoost Target$18.00 ➝ $19.00
6/30/2023Needham & Company LLCBoost TargetBuy$15.00 ➝ $17.00
6/30/2023Stifel NicolausBoost TargetBuy$15.00 ➝ $17.00
6/30/2023Credit Suisse GroupBoost TargetNeutral$13.00 ➝ $15.00
6/30/2023Wells Fargo & CompanyBoost TargetEqual Weight$13.00 ➝ $14.00
5/24/2023Bank of AmericaUpgradeNeutral ➝ Buy$16.50
5/1/2023DA DavidsonBoost Target$14.00 ➝ $16.00
4/28/2023GuggenheimBoost Target$16.00 ➝ $18.00
4/28/2023Morgan StanleyBoost Target$11.00 ➝ $14.00
4/21/2023Wells Fargo & CompanyBoost TargetEqual Weight$10.00 ➝ $13.00
4/11/2023StephensInitiated CoverageOverweight$18.00
3/28/2023Bank of AmericaBoost TargetNeutral$12.50 ➝ $14.50
3/24/2023Truist FinancialBoost Target$17.00
3/23/2023GuggenheimUpgradeNeutral ➝ Buy$16.00
2/9/2023Jefferies Financial GroupDowngradeBuy ➝ Hold$14.00
2/1/2023Raymond JamesInitiated CoverageOutperform$15.00
1/30/2023Truist FinancialBoost TargetBuy$12.00 ➝ $14.00
1/10/2023Needham & Company LLCReiterated RatingBuy$15.00
1/10/2023DA DavidsonLower Target$16.00 ➝ $14.00
1/6/2023Morgan StanleyLower TargetEqual Weight$12.00 ➝ $11.00
10/12/2022Wells Fargo & CompanyBoost TargetEqual Weight$8.00 ➝ $10.00
10/7/2022Credit Suisse GroupBoost TargetNeutral$9.00 ➝ $11.00
10/7/2022The Goldman Sachs GroupBoost TargetBuy$14.50 ➝ $16.00
10/7/2022Leerink PartnersBoost TargetMarket Perform$8.00 ➝ $13.00
10/4/2022Needham & Company LLCBoost TargetBuy$12.00 ➝ $15.00
10/4/2022Piper SandlerBoost TargetOverweight$12.00 ➝ $13.00
10/3/2022Canaccord Genuity GroupBoost TargetBuy$12.00 ➝ $15.00
9/21/2022The Goldman Sachs GroupBoost TargetBuy$13.00 ➝ $14.50
9/14/2022Morgan StanleyBoost TargetEqual Weight$9.00 ➝ $12.00
9/8/2022Piper SandlerReiterated RatingOverweight$12.00
9/7/2022Truist FinancialInitiated CoverageBuy$15.00
8/12/2022DA DavidsonInitiated CoverageBuy$16.00
7/5/2022Wells Fargo & CompanyBoost TargetEqual Weight$6.00 ➝ $8.00
7/1/2022Berenberg BankReiterated RatingBuy$11.00
7/1/2022Canaccord Genuity GroupLower TargetBuy$17.00 ➝ $12.00
7/1/2022The Goldman Sachs GroupLower TargetBuy$15.00 ➝ $13.00
6/17/2022Berenberg BankReiterated RatingBuy$11.00
5/26/2022The Goldman Sachs GroupLower TargetBuy$26.00 ➝ $15.00
5/2/2022Wells Fargo & CompanyUpgradeUnderweight ➝ Equal Weight$6.00
4/29/2022Canaccord Genuity GroupLower Target$34.00 ➝ $17.00
4/29/2022Stifel NicolausLower Target$16.00
4/29/2022Needham & Company LLCLower Target$33.00 ➝ $12.00
4/29/2022BTIG ResearchDowngradeBuy ➝ Neutral
4/29/2022Bank of AmericaDowngradeBuy ➝ Neutral$45.00 ➝ $9.00
4/29/2022Leerink PartnersDowngradeOutperform ➝ Market Perform$32.00 ➝ $8.00
4/29/2022Piper SandlerLower Target$22.00 ➝ $11.00
4/29/2022Morgan StanleyDowngradeOverweight ➝ Equal Weight$30.00 ➝ $9.00
4/29/2022Credit Suisse GroupDowngradeOutperform ➝ Neutral$33.00 ➝ $9.00
4/13/2022Piper SandlerLower Target$35.00 ➝ $22.00
4/11/2022Wells Fargo & CompanyInitiated CoverageUnderweight$9.00
4/6/2022GuggenheimInitiated CoverageNeutral
4/1/2022Credit Suisse GroupInitiated CoverageOutperform$33.00
3/3/2022Credit Suisse GroupLower TargetOutperform$43.00 ➝ $33.00
2/11/2022The Goldman Sachs GroupInitiated CoverageBuy$32.00
1/11/2022BTIG ResearchLower Target$60.00 ➝ $35.00
1/11/2022Stifel NicolausLower Target$40.00 ➝ $34.00
1/11/2022Morgan StanleyLower TargetOverweight$31.00 ➝ $30.00
1/11/2022Piper SandlerLower Target$45.00 ➝ $35.00
1/11/2022Needham & Company LLCLower TargetBuy$56.00 ➝ $33.00
12/17/2021Morgan StanleyLower TargetOverweight$56.00 ➝ $31.00
12/1/2021Jefferies Financial GroupInitiated CoverageBuy$33.00
10/11/2021Morgan StanleyLower TargetOverweight$68.00 ➝ $56.00
10/8/2021Berenberg BankReiterated RatingBuy$61.00
10/8/2021Credit Suisse GroupLower TargetOutperform$63.00 ➝ $62.00
10/8/2021Piper SandlerLower TargetPositive ➝ Overweight$60.00 ➝ $45.00
10/8/2021Needham & Company LLCLower TargetBuy$68.00 ➝ $56.00
10/8/2021Leerink PartnersLower TargetOutperform$58.00 ➝ $52.00
9/30/2021Berenberg BankInitiated CoverageBuy$61.00
9/17/2021Robert W. BairdUpgradeNeutral ➝ Outperform$58.00 ➝ $54.00
7/13/2021Robert W. BairdBoost TargetNeutral$54.00 ➝ $58.00
7/11/2021Leerink PartnersInitiated CoverageBuy$58.00
7/9/2021Stifel NicolausBoost TargetBuy$54.00 ➝ $64.00
7/9/2021Needham & Company LLCBoost TargetPositive ➝ Buy$59.00 ➝ $68.00
7/7/2021Credit Suisse GroupBoost TargetOutperform$59.00 ➝ $70.00
7/2/2021Morgan StanleyBoost TargetOverweight$60.00 ➝ $68.00
5/27/2021Robert W. BairdInitiated CoverageNeutral$54.00
5/6/2021Leerink PartnersUpgradeMarket Perform ➝ Outperform
4/27/2021Leerink PartnersReiterated RatingHold
4/15/2021Needham & Company LLCInitiated CoverageBuy$59.00
4/6/2021Morgan StanleyBoost TargetOverweight$57.00 ➝ $60.00
3/11/2021The Goldman Sachs GroupInitiated CoverageBuy
2/16/2021Piper SandlerBoost TargetOverweight$57.00 ➝ $60.00
1/15/2021BTIG ResearchBoost TargetPositive ➝ Buy$55.00 ➝ $60.00
1/15/2021Robert W. BairdBoost TargetOutperform$50.00 ➝ $55.00
1/15/2021Leerink PartnersBoost TargetMarket Perform$53.00 ➝ $56.00
1/15/2021Credit Suisse GroupUpgradeNeutral ➝ Outperform$45.00 ➝ $60.00
1/8/2021Credit Suisse GroupBoost TargetNeutral ➝ Neutral$42.00 ➝ $45.00
1/8/2021Robert W. BairdBoost TargetPositive ➝ Outperform$45.00 ➝ $50.00
1/8/2021Leerink PartnersBoost TargetMarket Perform$44.00 ➝ $53.00
1/8/2021Piper SandlerBoost TargetOverweight$55.00 ➝ $57.00
1/6/2021BTIG ResearchInitiated CoverageBuy$55.00
11/16/2020Stifel NicolausInitiated CoverageBuy$48.00
10/16/2020Morgan StanleyBoost TargetOverweight$37.00 ➝ $48.00
10/15/2020Bank of AmericaBoost TargetBuy$45.00 ➝ $51.00
10/15/2020DA DavidsonBoost TargetPositive ➝ Buy$45.00 ➝ $50.00
10/15/2020Leerink PartnersBoost TargetMarket Perform$40.00 ➝ $44.00
10/15/2020Robert W. BairdBoost TargetOutperform$40.00 ➝ $45.00
10/15/2020Piper SandlerBoost TargetOverweight$45.00 ➝ $55.00
10/8/2020Bank of AmericaBoost TargetBuy$42.50 ➝ $45.00
9/22/2020DA DavidsonInitiated CoverageBuy$45.00
8/14/2020Credit Suisse GroupBoost TargetNeutral$38.00 ➝ $40.00
8/14/2020Leerink PartnersBoost TargetMarket Perform$34.00 ➝ $40.00
7/27/2020Robert W. BairdInitiated CoverageOutperform$40.00
7/27/2020Leerink PartnersInitiated CoverageOutperform$34.00
7/27/2020Bank of AmericaInitiated CoverageBuy$37.00
7/27/2020Piper SandlerInitiated CoverageOverweight$45.00
7/27/2020The Goldman Sachs GroupInitiated CoverageBuy$39.00
7/27/2020Credit Suisse GroupInitiated CoverageNeutral$38.00
7/27/2020Morgan StanleyInitiated CoverageOverweight$37.00
(Data available from 12/24/2019 forward)

News Sentiment Rating

0.90 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 7 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/28/2024
  • 4 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/27/2024
  • 5 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
7/27/2024
  • 5 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/26/2024
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/25/2024
  • 9 very positive mentions
  • 14 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
10/25/2024
  • 4 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/24/2024
  • 9 very positive mentions
  • 6 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
12/24/2024

Current Sentiment

  • 9 very positive mentions
  • 6 positive mentions
  • 3 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Accolade logo
Accolade, Inc., together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and primary care physicians. It also provides medical opinion services to commercial customers; and navigation, care, and advocacy solutions. In addition, the company offers medical consultations that connect patients to qualified condition-specific specialists for adult and pediatric care; and primary care and mental health support solutions. It serves employers who provide employees and their families a single place to turn for their health, healthcare, and benefits needs. The company was incorporated in 2007 and is headquartered in Seattle, Washington.
Read More

Today's Range

Now: $3.42
Low: $3.37
High: $3.49

50 Day Range

MA: $3.51
Low: $3.15
High: $3.86

52 Week Range

Now: $3.42
Low: $3.08
High: $15.36

Volume

90,930 shs

Average Volume

1,090,305 shs

Market Capitalization

$275.44 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.07

Frequently Asked Questions

What sell-side analysts currently cover shares of Accolade?

The following Wall Street sell-side analysts have issued research reports on Accolade in the last year: Barclays PLC, Canaccord Genuity Group Inc., Guggenheim, Leerink Partners, Leerink Partnrs, Morgan Stanley, Needham & Company LLC, Piper Sandler, Raymond James, Stephens, Stifel Nicolaus, Truist Financial Co., Wells Fargo & Company, and William Blair.
View the latest analyst ratings for ACCD.

What is the current price target for Accolade?

0 Wall Street analysts have set twelve-month price targets for Accolade in the last year. Their average twelve-month price target is $8.96, suggesting a possible upside of 161.9%. Raymond James has the highest price target set, predicting ACCD will reach $16.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $5.00 for Accolade in the next year.
View the latest price targets for ACCD.

What is the current consensus analyst rating for Accolade?

Accolade currently has 3 hold ratings and 11 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ACCD.

What other companies compete with Accolade?

Other companies that are similar to Accolade include PropertyGuru Group, Custom Truck One Source, Paysafe, TELUS International (Cda) and Emerald. Learn More about companies similar to Accolade.

How do I contact Accolade's investor relations team?

Accolade's physical mailing address is 660 W. GERMANTOWN PIKE SUITE 500, PLYMOUTH MEETING PA, 19462. The company's listed phone number is 206-926-8100 and its investor relations email address is [email protected]. The official website for Accolade is accolade.com. Learn More about contacing Accolade investor relations.